Circulating Aging Biomarker Panel (GDF11, TGF-β1, B2M, Eotaxin) — Blood & Plasma Interventions
Emerging laboratory panel measuring circulating pro-aging and anti-aging plasma factors to guide blood-based longevity interventions.
Overview
The circulating aging biomarker panel represents an emerging approach to monitoring systemic aging via specific plasma proteins. Key pro-aging circulating factors (identified primarily through parabiosis and plasma proteomics research) include: TGF-β1 (transforming growth factor beta-1) — elevated in old plasma, inhibits muscle stem cell and neural stem cell activation; Beta-2 microglobulin (B2M) — elevated in old plasma, impairs hippocampal neurogenesis and cognitive function; Eotaxin-1 (CCL11) — elevated with age, impairs adult neurogenesis; VCAM-1 — elevated with age, promotes neuroinflammation. Anti-aging circulating factors include: GPLD1 (GPI-specific phospholipase D1) — elevated in young blood and in exercise-conditioned plasma, mediates exercise-induced neuroplasticity benefits; Klotho — declines with age, promotes longevity when overexpressed; GDF11 — controversial (see above). Gyori Lab (Stanford), Wyss-Coray Lab (Stanford), and Bhanu Bhanu Bhanu (Alkahest) have published comprehensive aging plasma proteomes using multi-analyte platforms. The Olink Proximity Extension Assay allows simultaneous measurement of 92-1,500+ plasma proteins from a single small sample.
Indications
- Longevity program baseline characterization
- Plasma dilution / TPE treatment monitoring
- Exercise intervention response assessment (GPLD1)
- Brain aging and cognitive decline risk stratification
Mechanism of Action
Old plasma contains elevated concentrations of pro-aging circulating factors that suppress stem cell niches, promote neuroinflammation, reduce synaptic plasticity, and impair tissue repair — these factors diffuse systemically affecting every organ
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Circulating Aging Panel (Olink, research lab) | Single blood draw (EDTA plasma, 2-4 mL) | Every 6-12 months or after intervention | Not standard clinical tests; available through research laboratories, TruDiagnostic, or longevity medicine specialty labs; Olink Proximity Extension Assay platforms |
Evidence Grade
GRADE C
Safety & Contraindications
- Blood draw only — no clinical risk
- Assay results should be interpreted by longevity-specialist physicians with knowledge of the evolving research context
- Not currently available as standard clinical tests — require research laboratory partnerships or specialized longevity labs